溶血对双抗原夹心法检测HIV抗体的影响

目的:探讨溶血对双抗原夹心法检测HIV抗体的影响.方法:制备HIV抗体阴性非溶血和配对溶血(Hb 2～7 g/L)血清48份.另制备HIV抗体阴性非溶血和重度溶血(Hb 80 g/L)血清1份、HIV抗体阳性非溶血和重度溶血(Hb 108 g/L)血清1份,用HIV抗体阴性血清对HIV抗体阴性重度溶血血清、HIV抗体阳性非溶血和配对重度溶血血清进行倍比稀释,得到不同溶血程度的样品.测定HIV抗体,检测溶血及不同溶血程度对HIV抗体的影响.结果:48份HIV抗体阴性非溶血和溶血血清比较,差异无统计学意义(t=0.078,P=0.938);对HIV抗体阴性重度溶血倍比稀释血清的A值和Hb浓度做相关性分析,两组间无相关性(r=-0.382,P=0.221);对HIV抗体阳性溶血、非溶血倍比稀释血清的A值进行比较,差异无统计学意义(t=0.236,P=0.817).△A(溶血血清A-非溶血血清A)与Hb浓度作相关性分析,两组间无相关性(r=0.149,P=0.644).结论:溶血对双抗原夹心法检测HIV抗体无影响.但是如果试剂反应孔包被、封闭的质量差可能引起Hb的非特异吸附而造成假阳性,故日常工作中要尽量避免样品溶血,严格按照全国艾滋病检测技术规范操作.     

第4代HIV抗原抗体联合检测试剂的评价

目的评价HIV(1+2)抗原抗体联合检测试剂,了解其是否适合于血液筛查。方法用HIV抗原抗体联合检测试剂和第3代HIV抗体检测试剂平行检测HIV感染或疑似感染样本205份、吸毒人群样本1486份、有既往献血史人群样本427份、献血和献浆人群样本7237份和丙型肝炎患者样本176份,对两种试剂检测结果不一致样本进行HIV p24抗原或RNA的检测,并分析其特异性和灵敏度。结果联合检测试剂检测HIV p24抗原的分析灵敏度为(2.5~5.0)U/ml,检测HIV抗体的分析灵敏度与第3代HIV抗体检测试剂相当。共检测出8996份HIV抗体阴性样本和503份HIV抗体阳性样本,与第3代试剂相比其特异为99.67%,灵敏度为100%,而且2份HIV感染“窗口期”样本也能检出。结论该试剂在增加HIV p24抗原检测的情况下,对HIV抗体检测的特异性和敏感性没有降低,可用于血液筛查以减少“窗口期”样本传播HIV的风险。     

评估第4代HIV酶联免疫法诊断试剂对静脉吸毒者感染窗口期的检测能力

目的应用BBI公司血清抗体阳转盘评价第4代人类免疫缺陷病毒（HIV）酶联免疫法诊断试剂（以下简称第4代试剂）对窗口期感染的检测能力,并应用其从静脉吸毒人群样本中筛查窗口期感染者,从而分析第四代试剂检测临床样本的特异性和敏感性。方法首先应用第3代HIV酶联免疫法诊断试剂筛查BBI血清阳转盘和收集的吸毒人群样本,阳性样本进一步用免疫印迹法确认。再用第4代试剂分别检测阴性和阳性样本,阴性样本中出现阳性反应者,进行p24抗原和HIV RNA病毒载量检测,证实是否为窗口期样本。对证实为窗口期的感染者随访至抗体阳转。结果用第3代试剂检测BBI阳转血清盘,未发现阳性样本;检测静脉吸毒人群样本2629份,发现HIV抗体阳性样本77份,经免疫印迹法（WB）确认均为阳性,阴性样本2552份。第4代试剂可检出BBI阳转血清盘第14天的窗口期样本;在2552份静脉吸毒人群抗体阴性样本中检出2份窗口期样本,一例随访至血清阳转,一例失访。临床检测特异性为99.2％,假阳性率0.8％（95％可信区间0．4％～1．1％）。结论第4代试剂比第3代试剂能够更早地发现HIV感染者,降低窗口期漏检,减少HIV传播。     

核酸检测对HIV筛查的影响

目的 分析开展核酸检测后青岛地区献血者HIV检测情况,探讨减少一遍ELISA检测及实施献血者归队的可行性.方法 对2012年9月13日～2013年6月1日期间的献血者标本,应用两种ELISA试剂检测HIV抗原/抗体,并用Roche Cobas S201血液筛查系统进行核酸检测,将HIV抗原/抗体反应性标本送至市疾控中心HIV确认实验室进行HIV确认.结果 ELISA方法共检出HIV抗原/抗体反应性标本90例,确认试验阳性13例,确认试验阴性77例,假阳性率85.56％(77/90),确认阳性者全部为ELISA双试剂反应性标本.HIV抗原/抗体非反应性标本经NAT检测无一例HIV RNA反应性;HIV抗原/抗体反应性标本90例,经NAT检测HIV RNA反应性标本13例,全部为ELISA双试剂反应性标本.结论 NAT与HIV确认试验有很好的符合性,开展NAT检测可以减少1遍HIV ELISA检测.     

安徽省六安市HIV抗体检验现状分析

20 0 0 - 11在送检的 HIV高危人群血清中 ,经我站 HIV抗体初筛实验室检测发现其中 1份标本为初筛阳性 ,可疑血清送安徽省艾滋病监测中心实验室进行确认 ,认定为 HIV- 1抗体阳性。这是我市 HIV抗体初筛实验室经过 3a多的努力 ,在全市范围内进行 HIV抗体检测发现的首例 HIV携带者。1　材料和方法1.1　标本来源　 1997～ 2 0 0 0年安徽省六安市所辖区内 6个血站和 1个单采浆站送检的血浆 (清 ) ,各性病门诊、长途汽车司机、暗娼等高危人群 ;各地委托检测血清和普通人群对照血清。1.2　实验仪器　BIO- RAD5 5 0型酶标仪 (美国产 ) ;D…     

第四代HIV抗原抗体检测试剂在血液筛查中的应用

目的研究第四代HIV抗原抗体检测试剂在血液筛查中的应用价值。方法对第四代HIV抗原抗体检测试剂进行灵敏度和重复性实验;分别采用第三代HIV抗体检测试剂和第四代HIV抗原抗体检测试剂对血液样本进行初复检,对第三代试剂检测阴性第四代试剂检测阳性的样本采用HIV核酸检测方法进行确认。结果第四代HIV抗原抗体检测试剂最低抗原检出浓度为1．25U／mL,孔间精密度为3．2％;2009年10月~2011年3月,共筛查样本23480例,其中13例第三代试剂结果阴性而第四代试剂结果阳性,经HIV核酸检测的方法进行确认,全部结果均为阴性。结论在血液筛查中引入第四代HIV检测试剂的试剂功效尚待进一步验证,在已经广泛开展HIV抗体检测的基础上,引入第四代HIV抗原抗体检测试剂还是引入核酸检测具有更好的成本效益比,是一个值得待探讨的课题。     

安徽省六安市HIV抗体检测现状分析

2000-11在送检的HIV高危人群血清中,经我站HIV抗体初筛实验室检测发现其中1份标本为初筛阳性,可疑血清送安徽省艾滋病监测中心实验室进行确认,认定为HIV-1抗体阳性.这是我市HIV抗体初筛实验室经过3a多的努力,在全市范围内进行HIV抗体检测发现的首例HIV携带者.     

367例 H IV‐1阳性样本 W B 确认结果的带型分析

目的通过对367例 HIV‐1抗体阳性者的蛋白印迹法(WB)的抗体条带分析,了解不同 HIV‐1感染人群其抗体WB带型分布的差异.方法采用WB法对HIV初筛有反应性样本进行HIV‐1抗体确认,WB阳性者按照不同年龄、性别、民族三组进行WB带型的统计分析.结果HIV‐1 gag基因编码的P39和P17抗体的阳性率在女性中明显高于男性(χ2值分别为6.386、10.872,均 P<0.05);年龄小于或等于50岁的 HIV‐1抗体阳性者gag基因编码的P39和pol基因编码的P31抗体阳性率分别明显高于年龄超过50岁者(χ2值分别为6.882、4.360,均P<0.05);而 HIV‐1抗体WB带型分布在不同民族之间的差异无统计学意义.结论 HIV‐1抗体WB带型分布在不同性别、不同年龄及不同民族人群间差异无统计学意义,HIV‐1 pol及gag基因编码的P39和P17蛋白的抗体产生在不同性别、不同年龄的人群间差异有统计学意义.这对 HIV 感染后病原检测和诊断包括传染源确定、传播途径追踪以及临床鉴别诊断具有非常重要的意义.     

EDTA-K2对双抗原夹心ELISA检测HIV抗体的影响

目的探讨乙二胺四乙酸二钾(EDTA-K2)对双抗原夹心酶联免疫吸附试验(ELISA)检测人类免疫缺陷病毒(HIV)抗体的影响。方法用HIV抗体阴性和阳性静脉血分别制备EDTA-K2浓度为1.5、2.5、5、10、15、20、25、30、35、40 mg/mL的抗凝血并留取无抗凝剂血,分别分离血浆和血清,测定各样本HIV抗体,读取吸光度(A)值,对A值与EDTA-K2浓度进行相关性分析;制备EDTA-K2最终浓度分别为1.5、2.5、5、10 mg/mL的HIV抗体阳性和阴性抗凝血各20份并留取无抗凝剂血,分别分离血浆和血清,平行测定各样本HIV抗体,血浆与血清样本进行配对t检验。结果 EDTA-K2浓度与HIV抗体阴性样本A值无相关关系(P=0.933),与HIV抗体阳性样本A值呈明显负相关(P<0.01);当EDTA-K2≥5 mg/mL时,HIV抗体阳性血浆样本A值明显低于血清样本(P<0.01),当EDTA-K2≤2.5 mg/mL时,血浆与血清样本A值比较,差异无统计学意义(P>0.05)。结论EDTA-K2对HIV抗体阴性样本测定无干扰;血浆EDTA-K2≤2.5 mg/mL时,对HIV抗体阳性样本测定无干扰,EDTA-K2≥5 mg/mL时,对HIV抗体阳性样本测定呈明显负干扰。     

免疫层析法在HIV(1/2)抗体检测中的应用

卫生部要求 HIV初筛实验室必须备有两种不同实验原理的试剂 ,对可疑结果进行复检。国内已经推广使用 ELISA双抗原夹心法检测 HIV(1 / 2 )抗体 ,笔者发现初筛复检用免疫层析法检测 HIV(1 / 2 )抗体 ,具有较高的准确性。为了进一步验证其结果 ,与 ELISA双抗原夹心法进行比较 ,实验结果如下。1　材料和方法1 .1　血清标本　 HIV(1 / 2 )抗体阳性血清 45份 ,分别由丽珠、华美试剂公司提供 ,本院住院患者血清标本 2 0 0 0份。1 .2　试剂　免疫层析法 :批号 2 0 0 30 81 8,美国雅培制药有限公司产品 ,HIV(1 / 2 )快速检测试剂 ;ELISA…     

Multicenter evaluation of a new 4th generation HIV screening assay Elecsys HIV combi

Fourth-generation screening assays which permit a simultaneous detection of human immunodeficiency virus (HIV) antigen and antibody reduce the diagnostic window on average by four days in comparison to third-generation antibody assays. Recently, the new automated Elecsys HIV combi was compared in a multicenter study to alternative fourth- and third-generation assays, p24 antigen test and HIV-1 RNA RT-PCR. A total of 104 serocon-version panels, samples of the acute phase of infection after seroconversion (n = 33), anti-HIV-1 positive specimens (n = 572) from patients in different stages of the disease, 535 subtyped samples from different geographical locations, including group M (subtypes A-J) and group O, anti-HIV-2 positive sera (n = 364), dilutions of cell culture supernatants (n = 60) infected with different HIV-1 subtypes, selected performance panels, 8406 unselected samples from blood donors originating from different blood transfusion centers, 3810 unselected sera from daily routine and from hospitalized patients, 9927 unselected samples from South Africa and 1943 potentially interfering samples were tested with the Elecsys HIV combi. Elecsys HIV combi showed a comparable sensitivity to HIV-1 Ag stand-alone assays for early detection of HIV infection in seroconversion panels. The mean time delay of Elecsys HIV combi (last negative sample + 1 day) in comparison to HIV-1 RT-PCR for 92 panels tested with both methods was 3.23 days. The diagnostic window was reduced with Elecsys HIV combi between 1.56 and 5.32 days in comparison to third-generation assays. The specificity of Elecsys HIV combi in blood donors was 99.80% after repeated testing. Our results show that a fourth-generation assay with improved specificity and sensitivity like the Elecsys HIV combi is suitable for blood donor screening due to its low number of false positives and since it detects HIV p24 antigen with a comparable sensitivity to single antigen assays.     

HBsAg/TP抗体/HIV抗体胶体金联合检测试剂在献血者筛查中的应用评价

目的 评价乙型肝炎病毒表面抗原(HBsAg)、梅毒螺旋体抗体(TP抗体)和人类免疫缺陷病毒抗体(HIV抗体)胶体金联合检测试剂的检测灵敏性、特异性和重复性,以及应用于献血筛查的意义.方法 采用胶体金联合检测试剂分别对2 250份正常献血者血液标本、85份HBsAg阳性标本,78份TP抗体阳性标本和62份HIV抗体阳性标本进行检测,并与参比试剂检测结果进行比较.结果 胶体金联合检测试剂与TP抗体参比试剂的总符合率、灵敏度(阳性符合率)和特异性(阴性符合率)分别为99.87%,100%和99.87%;与HBsAg参比试剂的总符合率、灵敏度和特异性分别为99.82%,94.74%和99.87%,与HIV抗体参比试剂的总符合率和特异性为100%,各项检测结果差异均无统计学意义(χ2=0.36,P>0.05;χ2=0.09,P>0.05;χ2=0.08,P>0.05).胶体金联合检测试剂实验重复性阳性符合率为100%.结论 胶体金联合检测试剂具有反应速度快,操作更加简单和快捷、灵敏度高、特异性和重复性好,适用于献血前血液筛查.     

Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples

summary .  Since the introduction in the mid-1980s, HIV testing has gradually improved both in terms of sensitivity and specificity. The so-called fourth generation of tests, combined HIV antigen/antibody assays, has now been introduced. This study compares three automated combined assays with older third-generation antibody assays in large-scale screening. Serum samples from routine screening of blood and plasma donors and clinical samples were investigated for specificity evaluation. Three fourth-generation combination assays from one manufacturer were compared with three older third-generation antibody assays from the same manufacturer. More than 40 000 samples per assay were included. For sensitivity, selected panels of confirmed HIV-1- and HIV-2-positive samples as well as seroconversion samples (HIV-1) from commercial panels and also from patients who appeared during the evaluation were used. The specificities of the fourth-generation tests were 99·91% (AxSYM), 99·95% (ARCHITECT) and 99·97% (PRISM) after repeated testing. Some specificity variation between reagent batches was observed. All HIV-1-positive samples were reactive by the three fourth-generation systems. HIV-1 seroconversion samples and panels were reactive earlier than by antibody-only tests. As for HIV-2 samples, AxSYM failed to detect one ( n  = 40), whereas PRISM and ARCHITECT detected all ( n  = 16 for PRISM and n  = 52 for ARCHITECT). The new HIV antigen/antibody combination assay systems were found to have high sensitivity and specificity. The instruments provided a rational and easy way of testing at large scale.     

两种检测模式在人类免疫缺陷病毒筛查实验室诊断中的比较

目的对比分析人类免疫缺陷病毒（HIV）抗体不同检测模式的检测效果。方法采用两种检测模式对每一份血液标本进行HIV抗体初筛检测,对比分析两种组合模式的检测结果的阴、阳性,由HIV确证实验室对初筛阳性标本进行确认,并对两种组合模式的检测效果进行评价。结果在26 482例血液标本中,模式一初筛有31例阳性标本,阳性率为11.71/万,其中4份确认为阳性,其灵敏度和特异性分别为100%和99.90%;模式二初筛有40例阳性标本,阳性率为15.10/万,其中4份确认为阳性,其灵敏度和特异性分别为100%和99.86%。两种组合模式初筛检测HIV抗体的阳性率及其灵敏度和特异性差异均无统计学意义（P〉0.05）。结论在进行HIV抗体初筛时,国产试剂组合模式可以替代进口试剂组合模式。     

Performance analysis among multiple fully automated anti-SARS-CoV-2 antibody measurement reagents: A potential indicator for the correlation of protection in the antibody titer

BackgroundTo evaluate the performance of various reagents in automated analyzers for antibody detection against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).MethodsUsing 100 serum samples from 100 individual patients diagnosed with SARS-CoV-2 infection, the precision, linearity, determination agreement, and correlation of five qualitative reagents (Elecsys Anti-SARS-CoV-2, ARCHITECT SARS-CoV-2 IgG, ARCHITECT SARS-CoV-2 IgM, Access SARS-CoV-2 IgM, and SARS-CoV-2 IgM) and four quantitative reagents (Elecsys Anti-SARS-CoV-2 S, ARCHITECT SARS-CoV-2 IgG II, Access SARS-CoV-2 IgG 1st IS, and SARS-COV-2 IgG S) were analyzed. A surrogate virus-neutralizing test (sVNT) kit was used to evaluate the measurement value of each quantitative reagent corresponding to the amount of neutralizing antibody, similar to that of patients in the late stage of infection.ResultsPrecision and linearity were found to be sufficient for clinical use. Five discrepant samples were observed in the positive and negative judgments of the qualitative reagents for IgG, and one discrepant sample was observed in the qualitative reagent for IgM. Although the measurement values of the quantitative reagents were different, they were correlated with each reagent. The reference values inferred from the sVNT were Elecsys Anti-SARS-CoV-2: 71.8 U/L, ARCHITECT SARS-CoV-2 IgGⅡ: 2976.3 AU/mL, Access SARS-CoV-2 IgG 1st IS: 689.6 IU/mL, and SARS-CoV-2 IgG S: 19.3 U/L.ConclusionsThe performance observed for each anti-SARS-CoV-2 antibody detection reagent was sufficient. The reference values based on the inhibition rate of sVNT have potential as indicators of the correlation of protection and are expected to be leveraged in automated antibody tests.     

Performance characteristics of a new rapid immunochromatographic test for the detection of antibodies to human immunodeficiency virus (HIV) types 1 and 2

Diagnostic kits for the detection of human immunodeficiency virus (HIV) antibodies have reached an unprecedented number. But choice of an ideal, cost-effective, and rapid test for HIV infection is of immense value for use in developing countries like India, where resources are limited. In this study we have evaluated the performance characteristics of the rapid immunochromatographic HIV test kit First Response HIV 1-2.O. First, the laboratory archived 450 characterized plasma/serum specimens, which were tested on First Response HIV 1-2.O. Second, a total of 134 consecutive voluntary counseling and testing (VCT) specimens were also tested and positive specimens were further confirmed with HIV TRI-DOT. All these VCT specimens were cross-checked with HIV double-enzyme-linked immunosorbent assay (ELISA) (Murex and Vironostika), and the results were matched. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and efficiency of First Response HIV 1-2.O with the 450 characterized specimens was 100% for HIV-1 with reference assay. The results in the VCT algorithm were correlating with double-ELISA. In the HIV-2 analysis, five HIV-2-positive specimens in First Response HIV 1-2.O were found to be HIV-2-indeterminate on Western blot. HIV TRI-DOT was unable to pick up two HIV-2 Western blot-positive specimens. First Response HIV 1-2.O has several advantages: low-cost (U.S. $0.70); only 10 microL of specimen; involves only two steps; room temperature storage; ability to differentiate HIV-1 and 2; and use of whole blood specimen. Hence this test kit could be suitable for initial screening in the HIV testing algorithm in resource-limited settings. J. Clin. Lab. Anal. 22:178-185, 2008. (c) 2008 Wiley-Liss, Inc.     

Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels

BACKGROUND: Accurate determination of the infectious window period (IWP) that remains with individual-donation (ID) or minipool (MP) NAT compared to those with serology assays is essential for residual risk estimations.
STUDY DESIGN AND METHODS: The relative sensitivity of the Procleix Tigris system (Gen-Probe/Chiron) used in ID-NAT format and cobas s 201 (Roche Molecular Systems) applied in 1:6 diluted samples to mimic six-minipool (MP6) nucleic acid test (NAT) was assessed by quadruplicate testing of five seroconversion panels per marker. A mathematical analysis based on the log-linear increase of viremia in the ramp-up phase, as established with bDNA 3.0 assays enabled estimation of the IWP for human immunodeficiency virus (HIV) and hepatitis B virus (HBV) assays.
RESULTS: The mean IWPs were Tigris HIV RNA 5.5 days, s 201 (1:6) HIV RNA 7.4 days, GenScreen Plus p24/anti-HIV 17.8 days, PRISM anti-HIV 19.0 days, Tigris HBV DNA 20.6 days, s 201 (1:6) HBV DNA 22.6 days, Bio-Rad hepatitis B surface antigen (HBsAg) 37.8 days, and PRISM HBsAg 35.5 days. At estimated 50 percent NAT seroconversion rates, s 201 (1:6) and Tigris showed mean window-period reduction times (WPRTs) of 30.5 to 35.5 days to hepatitis C virus antibody (anti-HCV) assays, 10.4 to 13.5 days to anti-HIV, or combination p24/anti-HIV assays and 12.8 to 17.2 days to HBsAg assays.
CONCLUSIONS: Tigris ID-NAT detected HIV RNA 2 days earlier than s 201 MP6-NAT, but the difference in sensitivity between the two NAT systems was not significant in HBV seroconversion panels. Insufficient seroconversion samples were available for reliable modeling of WPRT in early HCV infection, but 1.4 to 2.0 days could be predicted by translating analytical sensitivity data. Both multiplex NAT systems demonstrate significant WPRTs compared to (combined) antigen and antibody assays.     

新型丙型肝炎病毒抗体检测试剂Elecsys anti-HCV Ⅱ的性能评价与比较

目的评价新上市的丙型肝炎病毒抗体(抗-HCV)筛查试剂Elecsys anti-HCV Ⅱ的性能,并与其他两种临床上广泛应用的同类试剂进行性能比较。 方法使用罗氏Elecsys anti-HCV Ⅱ、雅培Architect anti-HCV和强生Vitros anti-HCV 3种试剂,平行检测4个HCV血清转换盘、861份临床常规样本、100份抗-HCV检测临界阳性样本及178份HIV感染患者样本。抗-HCV确诊试验为重组免疫印迹法(RIBA 3.0)或HCV RNA定量检测。此外,使用Elecsys anti-HCV Ⅱ检测203份不同HCV基因型样本以评价其基因型覆盖度。 结果相比Architect和Vitros anti-HCV,Elecsys anti-HCV II可提前7～14d检测到HCV感染后抗-HCV的产生;在检测临床常规样本(包括抗-HCV临界阳性样本)时,Elecsys anti-HCV Ⅱ有100%的敏感度及良好的特异度;70.22%(125/178)HIV感染患者样本为HCV RNA阳性,Elecsys anti-HCV Ⅱ可检测出其中97.60%(122/125)样本中的抗-HCV;Elecsys anti-HCV Ⅱ可能低估3b型样本的抗-HCV水平。 结论Elecsys anti-HCV Ⅱ可进一步缩短HCV感染后的检测窗口期,可灵敏、特异地检测临床样本包括免疫缺陷患者样本中的抗-HCV,适用于临床HCV感染的筛查,但对其检测特定HCV基因型样本的性能尚需纳入更多样本深入研究。     

ARCHITECT HIV Ag/Ab combo筛查HIV弱反应性结果的追踪

目的 应用化学发光微粒子免疫技术对人类免疫缺陷病毒（HIV）抗原抗体联检的弱反应性结果的分析,探讨其在临床中的诊断价值.方法 应用化学发光微粒子免疫技术检测的22例HIV弱反应性标本,分别用第三、第四代HIV试剂,采用ELISA对HIV抗体进行重复检测,并与疾控中心确证试验中的免疫印迹法结果进行比对.结果 化学发光微粒子免疫技术初筛的22份弱反应性的标本,用ELISA第三代和第四代试剂复检,结果均为阴性;确证实验室检测,ELISA复核1例为有反应性,蛋白印迹结果为17份样本有一条带或多条带HIV抗原阳性（占77.3％）.结论 化学发光微粒子免疫技术在对HIV抗原抗体联检具有更高的敏感度,对艾滋病诊断具有重要意义.